Mercer Global Advisors
LRMR icon

Mercer Global Advisors’s Larimar Therapeutics LRMR Stock Holding History

Mercer Global Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
68,934
+51,850
+304% +$206K ﹤0.01% 3194
2026
Q1 		$76.9K Buy
+17,084
New +$68.3K ﹤0.01% 3074

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Mercer Global Advisors's LRMR Position: Q2 2026 in Review

Mercer Global Advisors increased its Larimar Therapeutics (LRMR) stake by 304% in Q2 2026, buying an estimated $206K and bringing the position to 68,934 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Mercer Global Advisors first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Mercer Global Advisors held 68,934 shares of Larimar Therapeutics worth $210K as of Q2 2026.
  • Mercer Global Advisors bought 51,850 Larimar Therapeutics shares in Q2 2026, an estimated $206K.
  • Larimar Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3194 holding.
  • Mercer Global Advisors first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.